Therapeutic developments in cytomegalovirus retinitis

Bibliography

• MITZ L, DREW WL, MINER RC et al: Cytomegalovirusinfections in homosexual men. Ann. Intern. Med. (1983) 99:326–329.
   PubMed Web of Science ®Google Scholar
• COLLIER AC, MEYERS JD, COREY L et al: Cytomega-lovirus infection in homosexual men: relationship to sexual practices, antibody to human immunodefi-ciency virus and cell-mediated immunity. Am. J. Med. (1987) 82:593–601.
   PubMed Web of Science ®Google Scholar
• DREW WL, MINTZ L, MINER RC et al.: Prevalence of cytomegalovirus in homosexual men. J. Infect. Dis. (1981) 143:188–192.
   PubMed Web of Science ®Google Scholar
• GALLANT JE, MOORE RD, RICHMAN DD et al.: Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. J. Infect. Dis. (1992) 166:1223–1227.
   PubMed Web of Science ®Google Scholar
• •This study describes the risk factors for CMV disease in the pre-HAART era.
   Google Scholar
• HOOVER DR, SAAH AJ, BACELLAR H et al: Clinical manifestations of AIDS in the era of Pneumocystis carinii prophylaxis. N. Engl. J. Med. (1993) 329:1922–1926.
   PubMed Web of Science ®Google Scholar
• DREW WL: Cytomegalovirus in patients with AIDS.Olin. Infect. Dis. (1992) 14:608–615.
   PubMed Web of Science ®Google Scholar
• D'ARMINIO MONFORTE A, MAININI F, TESTA L et al.: Predictors of cytomegalovirus disease, natural history and autopsy findings in a cohort of patients with AIDS. AIDS (1997) 11:517–524.
   Google Scholar
• PALELLA FJ, DELANY KM, MOORMAN AC et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl. J. Med. (1998) 338:853–860.
   PubMed Web of Science ®Google Scholar
• KUPPERMAN BD, PETTY JG, RICHMANN DD et al: Correlation between CD4+ counts and prevalence of cytomegalovirus and human immunodeficiency virus-related noninfectious retinal vasculopathy in patients with acquired immunodeficiency syndrome. Am. J. Ophthalmol. (1993) 115:575–582.
   PubMed Web of Science ®Google Scholar
• SAILLOUR F, BERNARD N, DEQUAE-MERCHADOU L et al.: Predictive factors of occurrence of cytomegalovirus disease and impact on the survival in the Aquitaine Cohort in France, 1985-1994. Group d'Epidemiologie Clinique du SIDA en Aquitaine. Acquir. Immune Defic. Syndr. Hum. Retrovirol (1998) 17:171–178.
   PubMed Web of Science ®Google Scholar
• JABS DA: Ocular manifestations of HIV infection. Trans. Am. Ophthalmol Soc. (1995) 93:623–683.
   PubMedGoogle Scholar
• LYLES RH, CHU C, MARGOLICK J et al.: HIV RNA and CD4 lymphocyte count relate differently to the occurrence of PCP, CMV and MAC disease. Abstracts of the 5th Confer-ence on Retroviruses and Opportunistic Infections. Chicago, IL, USA (1998).
   Google Scholar
• CURRIER JS, WILLIAMS PL, GRIMES JM et al.: Incidencerates and risk factors for opportunistic infections in a Phase III trial comparing indinavir + ZDV + 3TC to ZDV + 3TC. Abstracts of the 5th Conference on Retro viruses and Opportunistic Infections. Chicago, IL, USA (1998).
   Google Scholar
• FOSCARNET-GANCICLOVIR CYTOMEGALOVIRUS TRIAL:Clinical features of cytomegalovirus retinitis at diagnosis. Studies of ocular complications of AIDS Research Group in collaboration with AIDS Clinical Trial Group. Am. J. Ophthalmol (1997) 124:141–157.
   Google Scholar
• D'ARMINIO MONFORTE A, MAININI F, VAGO L et al.:Factors associated with increased risk for cytomega-lovirus disease in AIDS patients. J. Infect. Dis (1993) 168:1071–1072.
   Google Scholar
• HOOVER DR PENG Y, SAAH A et al: Occurrence of cytomegalovirus retinitis after human immunodefi-ciency virus immunosuppression. Arch. Ophthalmol. (1996) 114:821–827.
   PubMed Web of Science ®Google Scholar
• JABS DA, DUNN JP, ENGER C et al: Cytomegalovirus retinitis and viral resistance. Prevalence of resistance at diagnosis, 1994. Cytomegalovirus Retinitis and Viral Resistance Study Group. Arch. Ophthalmol. (1996) 114:809–814.
   Google Scholar
• HO M: Epidemiology of cytomegalovirus infection in man. In: Cytomegalovirus: Biology and Infection (2nd Edition). Ho M (Ed.), Plenum Publishing, New York, USA (1990:155–188.
   Google Scholar
• SALTZMAN RL, QUIRK MR, JORDAN MC: High levels of cirulating cytomegalovirus DNA reflect visceral organ disease in viremic immunosuppressed patients other than marrow recipients. J. Clin. Invest. (1992) 90:1832–1838.
   PubMed Web of Science ®Google Scholar
• DODT KK, JACOBSEN PH, HOFFMAN B et al.: Develop- ment of CMV disease may be predicted in HIV-infected patients by CMV polymerase chain reaction and the antigenemia test. AIDS (1997) 11:F21–F28.
   PubMed Web of Science ®Google Scholar
• •This study compares the predictive value of CMV PCR and pp65 antigen testing for CMV disease in AIDS.
   Google Scholar
• LANDRY ML & FERGUSON D: Comparison of quantita- tive cytomegalovirus antigenemia assay with culture methods and correlation with clinical disease. J. Clin. Microbiol. (1993) 31:2851–2856.
   PubMed Web of Science ®Google Scholar
• WETHERILL PE, LANDRY ML, ALCABES P et al.: Use of a quantitative cytomegalovirus (CMV) antigenemia test in evaluating HIV+ patients with and without CMV disease. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. (1996) 12:33–37.
   PubMedGoogle Scholar
• PODZAMCZER D, FERRER E, GARCIA A et al.: pp65 antige-nemia as a marker of future CMV disease and mortality in HIV-infected patients. Scand. J. Infect. Dis. (1997) 29:223–227.
   PubMed Web of Science ®Google Scholar
• SALZBERGER B, FRANZEN C, FATKENHEUER G et al: CMV-antigenemia in peripheral blood for the diagnosis of CMV disease in HIV-infected patients. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. (1996) 11:365–369.
   PubMedGoogle Scholar
• BEK B, BOECKH M, LEPENIES J et al.: High-levelsensitivity of quantitative pp65 cytomegalovirus (CMV) antigemia assay for diagnosis of CMV disease in AIDS patients and follow-up. J. Clin. Microbiology (1996) 34:457–459.
   PubMed Web of Science ®Google Scholar
• FRANCISCI D, TOSTI A, PREZIOSI R et al.: Role of antige-nemia assay in the early diagnosis and prediction of human cytomegalovirus organ involvement in AIDS patients. Eur. J. Clin. MicrobioL Infect. Dis. (1995) 14:498–503.
   PubMed Web of Science ®Google Scholar
• CASADO JL, ARRIZABALAGA J, MONTES M et al.: Incidence and risk factors for developing cytomega-lovirus retinitis in HIV-infected patients receiving protease inhibitor therapy. AIDS (1999) 13:1497–1502.
   PubMed Web of Science ®Google Scholar
• JACOBSON MA: Treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome. N Engl. J. Med. (1997) 337:105–114.
   PubMed Web of Science ®Google Scholar
• •Review of existing therapy for CMV retinitis in 1997.
   Google Scholar
• FREEMAN WR, FRIEDBERG DN, BERRY C et al.: Risk factors for development of rhegmatogenous retinal detachment in patients with cytomegalovirus retinitis. Am. J. Ophthalmol. (1993) 116:713–720.
   PubMed Web of Science ®Google Scholar
• MACDONALD JC. TORRIANI FJ, MORSE LS et al.: Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active anti-retroviral therapy. J. Infect. Dis. (1998) 177:1182–1187.
   Google Scholar
• TURAL C, ROMEU J, SICRERA G et al.: Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients. J. Infect. Dis. (1998) 177:1080–1083.
   PubMed Web of Science ®Google Scholar
• VRABEC TR, BALDASSANO VF & WHITCUP SM: Discon-tinuation of maintenance therapy in patients with quiescent cytomegalovirus retinitis and elevated CD4+ counts. Ophthalmology (1998) 105:1259–1264.
   PubMed Web of Science ®Google Scholar
• CRUMPACKER CS: Ganciclovir. N Engl. J. Med. (1996) 335:721–729.
   PubMed Web of Science ®Google Scholar
• PLOTKIN SA, DREW WL, FELSENTSEIN D eta].: Sensitivity of clinical isolates of human cytomegalovirus to 9-(1,3-dihydroxy-2-propoxymethy0 guanine. J. Infect. Dis. (1985) 152:833–834.
   Google Scholar
• AREVALO JF, GONZALEZ C, CAPPARELLI EV et al.: Intravitreous and plasma concentrations of ganciclovir and foscarnet after intravenous therapy in patients with AIDS and cytomegalovirus retinitis. J. Infect. Dis. (1995) 172:951–956.
   PubMed Web of Science ®Google Scholar
• SPECTOR SA, BUSCH DF, FOLLANSBEE S et al.: Pharma-cokinetics, safety and antiviral profiles of oral ganciclovir in persons infected with human immuno-deficiency virus: a Phase I/II study. J. Infect. Dis. (1995) 171:1431–1437.
   PubMed Web of Science ®Google Scholar
• DREW WL, IVES D, LALEZARI JP et al. Oral ganciclovir as maintenance therapy for cytomegalovirus retinitis in patients with AIDS. Syntex Cooperative Oral Ganciclovir Study Group. N. Engl. J. Med. (1995) 333:615–620.
   PubMed Web of Science ®Google Scholar
• LALEZARI J, FRIEDBERG D, BISSET J et al: A comparison of the safety and efficacy of 3G, 4.5G and 6G doses of oral ganciclovir versus IV ganciclovir for maintenance treatment of CMV retinitis. 11th International Confer-ence of AIDS. Vancouver, Canada (1996).
   Google Scholar
• INTRAVENOUS VERSUS ORAL GANCICLOVIR: European/Australian comparative study of efficacy and safety in the prevention of cytomegalovirus retinitis recurrence in patients with AIDS. The Oral Ganciclovir European and Australian Cooperative Study Group. AIDS (1995) 9:471–477.
   Google Scholar
• SPECTOR SA, MCKINLEY GF, LALEZARI JP et al.: Oralganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. N Engl. J. Med. (1996) 334:1491–1497.
   PubMed Web of Science ®Google Scholar
• JABS DA, ENGER C, DUNN JP et al.: Cytomegalovirusretinitis and viral resistance: ganciclovir resistance. J. Infect. Dis. (1998) 177:770–773.
   PubMed Web of Science ®Google Scholar
• DREW WL, MINER RC, BUSCH DF et al.: Prevalence ofresistance in patients receiving ganciclovir for serious cytomegalovirus infection. J. Infect. Dis. (1991) 163:716–719.
   PubMed Web of Science ®Google Scholar
• SMITH IL, CHERRINGTON JM, JILES RE et al.: High-level resistance of cytomegalovirus to ganciclovir is associ-ated with alterations in both UL97 and DNA polymerase genes. J. Infect. Dis. (1997) 175:69–77.
   Google Scholar
• JABS DA: Incidence of resistant cytomegalovirus (CMV) in patients being treated for CMV retinitis. Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, USA (1998).
   Google Scholar
• DUNN JP, MACCUMBER MW, FORMAN MS et al.: Viral sensitivity testing in patients with cytomegalovirus retinitis clinically resistant to foscarnet or ganciclovir. Am. J. Ophthalmol. (1995) 119:587–596.
   PubMed Web of Science ®Google Scholar
• GILBERT C, HANDFIELD J, TOMA E et al: Emergence and prevalence of cytomegalovirus U1L97 mutations associ-ated with ganciclovir resistance in AIDS patients. AIDS (1998) 12:125–129.
   PubMed Web of Science ®Google Scholar
• HOLLAND GN, LEVINSON RD, JACOBSON MA et al: Dose-related difference in progression rates of cytomegalovirus retinopathy during foscarnet maintenance therapy. AIDS Clinical Trial Group Protocol 915 Team. Am. J. Ophthalmol. (1995) 119:576–586.
   Google Scholar
• PALESTINE AG, POLIS MA, DESMIT MD et al: A random-ized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann. Intern. Med. (1991) 115:665–673.
   PubMed Web of Science ®Google Scholar
• STUDIES FOR OCULAR COMPLICATIONS OF AIDS RESEARCH GROUP IN COLLABORATION WITH THE AIDS CLINICAL TRIALS GROUP: Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl. J. Med. (1992) 326:213–220.
   PubMed Web of Science ®Google Scholar
• THE CYTOMEGALOVIRUS RETREATMENT TRIAL. THE STUDIES OF OCULAR COMPLICATIONS OF AIDS RESEARCH GROUP IN COLLABORATION WITH THE AIDS CLINICAL TRIALS GROUP: Combination foscarnet and ganciclovir therapy vs. monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with aids. Arch. Ophthalmology (1996) 114:23–33.
   Google Scholar
• HITCHCOCK MJ, JAFFE HS, MARTIN JC et al.: Cidofovir, a new agent with potent anti-herpesvirus activity. Antiviral Chem. Chemo. (1996) 7:115–127.
   Web of Science ®Google Scholar
• LALEZARI JP, STAGG RJ, KUPPERMANN BD et al: Intrave-nous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial. Ann. Intern. Med. (1997) 126:257–263.
   PubMed Web of Science ®Google Scholar
• PARENTAL CIDOFOVIR FOR CYTOMEGALOVIRUS RETINITIS IN PATIENTS WITH AIDS: The HPMPC periph-eral cytomegalovirus retinitis trial. A randomized, controlled trial. Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Ann. Intern. Med. (1997) 126:264–274.
   Google Scholar
• LALEZARI JP, KEMPER C, STAGG RJ: A randomized, controlled study of the safety and efficacy of intrave-nous cidofovir (CDV, HPMPC) for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS. Abstracts of the 1 1 th International Conference on AIDS. Vancouver, Canada (1996).
   Google Scholar
• LALEZARI JP, DREW WL, GLUTZER E et al.: (S)-1-[3-hydroxy-2-(phosphonylmethoxy) propyl]cytosine (cidofovir): results of a Phase I/II study of a novel antiviral nucleotide analogue. J. Infect. Dis. (1995) 171:88–96.
   Google Scholar
• KIRSCH LS, AREVALO JF, DE CLERCQ E et al.: Phase I/II study of intravitreal cidofovir for the treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Am] Ophthalmol. (1995) 119:466–476.
   Google Scholar
• DAVIS JL, TASKINTUNA I, FREEMAN WR: Iritis andhypotony after treatment with intravenous cidofovir for cytomegalovirus retinitis. Arch. Ophthalmol. (1997) 115:733–737.
   PubMed Web of Science ®Google Scholar
• SKIEST DJ, DUONG M, PARK S et al.: Complications oftherapy with intravenous cidofovir: severe nephro-toxicity and anterior uveitis. Inf. Dis. Clin. Prac. (1999) 8:151–157.
   Web of Science ®Google Scholar
• PALAUE LA, TUFTY GT, PANKEY GA: Recurrent iritisafter administration of cidofovir. Clin. Infect. Dis. (1997) 25:337–338.
   PubMed Web of Science ®Google Scholar
• FRIEDBERG DN: Hypotony and visual loss with intrave-nous cidofovir treatment of cytomegalovirus retinitis. Arch. Opthalmol. (1997) 115:801–2.
   PubMed Web of Science ®Google Scholar
• VANDERCAM B, MOREAU M, GOFFIN E et al.: Cidofovir-induced end-stage renal failure. Clin. Inf. Dis. (1999) 29:948–949.
   PubMed Web of Science ®Google Scholar
• STUDIES OF OCULAR COMPLICATIONS OF AIDS RESEARCH GROUP IN COLLABORATION WITH THE AIDS CLINICAL TRIALS GROUP Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Arch. Intern. Med. (1995) 155:65–74.
   PubMed Web of Science ®Google Scholar
• MARTIN DF, FERRIS FL, PARKS DJ et al.: Ganciclovir implant exchange. Timing, surgical procedure and complications. Arch. Ophthalmol. (1997) 115:1389–1394.
   PubMed Web of Science ®Google Scholar
• MARTIN DF, PARKS DJ, MELLOW SD et al.: Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized controlled clinical trial. Arch. Ophthalmol (1994) 112:1531–1539.
   PubMed Web of Science ®Google Scholar
• MUSCH DC, MARTIN DF, GORDON JF et al.: Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. The Ganciclovir Implant Study Group. N Engl. J. Med. (1997) 337:83–90.
   PubMed Web of Science ®Google Scholar
• MARTIN D, KUPPERMANN BD, WOLITZ R et al.: Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. N Engl. J. Merl. (1999) 340:1063–1070.
   PubMed Web of Science ®Google Scholar
• •This study demonstrated the benefit of adding oral ganciclovir to the ganciclovir implant.
   Google Scholar
• MORLET N, YOUNG S, NAIDOO D et al.: High dose intravitreal ganciclovir injection provides a prolonged therapeutic intraocular concentration. Br. J. Ophthalmol. (1996) 80:214–216.
   PubMed Web of Science ®Google Scholar
• YOUNG S, MORLET N, BESEN G et al.: High dose (2000mcg) intravitreous ganciclovir in the treatment of cytomegalovirus retinitis. Ophthalmology (1998) 105:1404–1410.
   PubMed Web of Science ®Google Scholar
• DIAZ-LLOPIS M, CHIPONT E, SANCHEZ S et al.: Intravitreal foscarnet for cytomegalovirus retinitis in a patient with acquired immune deficiency syndrome. Am. J. Ophthalmol. (1992) 114:742–747.
   PubMed Web of Science ®Google Scholar
• DIAZ-LLOPIS M, ESPANA E, MUNOZ G et al.: High dose intravitreal foscarnet in the treatment of cytomega-lovirus in AIDS. Br. J. Ophthalmol. (1997) 78:120–124.
   Google Scholar
• TASKINTUNA I, RAHHAL RM, RAO NA et al.: Adverse events and autopsy findings after intravitreous cidofovir (HPMPC) therapy in patients with acquired immune deficiency syndrome. Ophthalmology (1997) 104:1827–1837.
   PubMed Web of Science ®Google Scholar
• KIRSCH LS, AREVALO JF, CHAVEZ DE LA PAZ E et al.: Intravitreal cidofovir (HPMPC) treatment of cytomega-lovirus retinitis in patients with acquired immunodefi-ciency syndrome. Ophthalmology (1995) 102;533–542.
   Google Scholar
• TASKINTUNA I, RAHHAL FM, ARE VALO JF et al.: Low-dose intravitreal cidofovir (HPMPC) therapy of cytomega-lovirus retinitis in patients with acquired immunodefi-ciency syndrome. Ophthalmology (1997) 104:1049–1057.
   Google Scholar
• PERRY CM & BALFOUR JAB: Fomivirsen. Drugs (1999) 57:375–380.
   PubMed Web of Science ®Google Scholar
• HUTCHERSON SL, PALESTINE AG, CANTRILL HL et al.:Antisense oligonucleotide safety and efficacy for CMV retinitis in AIDS patients. Abstracts of the 35th Intersci-ence Conference on Antimicrobial Agents and Chemotherapy San Francisco, CA, USA (1995).
   Google Scholar
• WHITLEY RJ, JACOBSON MA, FRIEDBERG DN et al: Guidelines for the treatment of cytomegalovirus disease in patients with AIDS in the era of potent anti-retroviral therapy. Recommendations of an International panel. Arch. Intern. Med. (1998) 158:957–969.
   PubMed Web of Science ®Google Scholar
• ••Excellent reference which discusses the treatmentrecommendations made by a panel of experts.
   Google Scholar
• INVESTIGATOR'S BROCHURE FOR VALGANCICLOVIR (Ro107–9070), 4th Version, (August 1999).
   Google Scholar
• BROWN F, ARUM I, FRANCIS G et al.: Ganciclovir prodrug (RS-79070) multiple dose, dose-ranging study with effect of food. Abstracts of the 4th Conference on Retroviruses and Opportunistic Infections. Washington, DC, USA (1997).
   Google Scholar
• DROBYSKI WR, GOTTLIEB M, CARRIGAN D eta].: Phase I study of safety and pharmacokinetics of a human anticytomegalovirus monoclonal antibody in allogenic bone marrow transplant recipients. Transplantation (1991) 51:1190–1196.
   Google Scholar
• MSL-109 ADJUVANT THERAPY FOR CYTOMEGALOVIRUS RETINITIS IN PATIENTS WITH ACQUIRED IMMUNODEFI-CIENCY SYNDROME: The Monoclonal Antibody Cytomegalovirus Retinitis Trial. The Studies of Ocular Complications of AIDS Research Group. AIDS Clinical Trials Group. Arch. Ophthalmol (1997) 115:1528–1536.
   PubMed Web of Science ®Google Scholar
• TOLPIN M, POLLARD R, TIERNEY M et al.: Combination therapy of cytomegalovirus (CMV) retinitis with a human monoclonal anti-CMV antibody (SDZ MSL 109) and either ganciclovir (DHPG) or foscarnet (PSA). Abstracts of the 11th International Conference on AIDS. Berlin, Germany (1993).
   Google Scholar
• CUNDY KC, BARDITCH-CROVO P, PETTY BG et al.: Clinical pharmacokinetics of 14( (S)-2-hydroxy-2--oxo-1,4,2-dioxaphosphorian-5-yOmethylicytosine in human immunodeficiency virus infected patients. Antimicrob. Agents Chemoth. (1999) 43:271–277.
   PubMedGoogle Scholar
• TENNEY DJ, YAMANAKA G, VOSS SM et al.: Lobucavir is phosphorylated in human cytomegalovirus-infected and -uninfected cells and inhibits the viral DNA polymerase. Antimicrob. Agents Chemoth. (1997) 41:2680–2685.
   PubMed Web of Science ®Google Scholar
• IRELAND C, LEESON PA, CASTANER J: Lobucavir. Drugs Future (1997) 22:359–370.
   Google Scholar
• CUNDY KC, BARDITCH-CROVO P, WALKER RE et al.: Clinical pharmacokinetics of adefovir in human immunodeficiency virus Type 1-infected patients. Antimicrob. Agents Chemother. (1995) 39:241–2405.
   PubMedGoogle Scholar
• BARDITCH-CROVO P, TOOLE J, HENDRIX CW et al.: Anti-human immunodeficiency virus activity, safety and pharmacokinetics of adefovir dipivoxil in HIV-infected patients. J. Infect. Dis. (1997) 176:406–413.
   PubMed Web of Science ®Google Scholar
• HALLENBERGER S, BUERGER I, TRAPPE J et al.: Mechanism of antiviral action of BAY 38-4766 - a novel non-nucleosidic inhibitor of human cytomegalovirus replication. Posters of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA (1999).
   Google Scholar
• ECKENBERG P, REEFSCHLAEGER J, BENDER W et al. Structure-activity relationships of BAY 38-4766 - a novel non-nucleosidic inhibitor of human cytomega-lovirus replication. Posters of the 39th Interscience Confer-ence on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA (1999).
   Google Scholar
• NAGELSCHMITZ J, MOELLER JG, STASS H et al.: Safety, tolerability and pharmacokinetics of single oral doses of BAY 38–4766 - a novel, non-nucleosidic inhibitor of human cytomegalovirus (HCMV) replication - in healthy male subjects. Posters of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA (1999).
   Google Scholar
• LALEZARI JP, ABERG JA, WANG LH et al.: In vivo anti-CMV activity, safety and pharmacokinetics (PK) of oral 1263W94 in HIV-infected subjects with asymptomatic CMV shedding. 5th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, USA (1998).
   Google Scholar
• BIRON KK, DAVIS MG, STANAT SC et al.: Antiviral activityand mechanism of action of 1263W94, a benzimida-zole riboside inhibitor of cytomegalovirus. Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA (1996). Vonda F Hoffmann & Daniel J Skiest2
   Google Scholar